DEF: Boston Scientific Sets Stage for 2025 with Annual Stockholder Meeting

Boston Scientific invites stockholders to its virtual Annual Meeting on May 1, 2025, to vote on key proposals including director elections and executive compensation.

Summary

• Boston Scientific will hold its Annual Meeting of Stockholders virtually on May 1, 2025.
• Stockholders of record as of March 7, 2025, are eligible to vote.
• The meeting will address the election of ten director nominees, an advisory vote on executive compensation, ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2025 fiscal year, and a stockholder proposal regarding simple majority voting.
• The Board recommends voting FOR the election of each director nominee, FOR the executive compensation, and FOR the ratification of Ernst & Young LLP's appointment.
• The company achieved one of its strongest years in its 45-year history, fueled by acquisitions, product launches (approximately 100), clinical trials, and expanded manufacturing capacity.
• In 2024, Boston Scientific acquired Axonics, Silk Road Medical, Cortex, and SoundCath, and entered into agreements to acquire Intera Oncology and Bolt Medical.
• The company aims to consistently be the highest-performing large cap company in medtech, focusing on above market revenue growth, expanded operating margins, double-digit adjusted EPS growth and strong cash flow generation.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook, highlighting strong financial performance, strategic acquisitions, and a commitment to innovation and growth. The tone is optimistic and confident, suggesting a strong belief in the company's future prospects.

Positives

• Boston Scientific achieved one of its strongest years in its 45-year history in 2024.
• The company launched approximately 100 products in 2024.
• Boston Scientific expanded its manufacturing and supply chain capacity to meet growing demand.
• The company helped improve the lives of more than 44 million patients around the world in 2024.
• The company celebrated treating more than 500,000 patients globally with WATCHMAN LAAC technology.
• The company's FARAPULSE PFA System has treated more than 200,000 patients.

Risks

• The document mentions that if underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from expectations.

Future Outlook

The company continues to focus on long-range financial goals of above market revenue growth, expanded operating margins, double-digit adjusted EPS growth and strong cash flow generation, aiming to consistently be the highest-performing large cap company in medtech.

Management Comments

• Our growth strategy at Boston Scientific over the past decade has focused on category leadership: to become the go-to company in the medical specialties we serve.
• We aim to consistently be the highest-performing large cap company in medtech, and we are making investments today to drive growth over the long term.
• Boston Scientific is in an excellent position to continue increasing value for customers, employees and stockholders.

Industry Context

The announcement highlights Boston Scientific's strategy to deepen its focus in existing areas and expand into high-growth markets and adjacencies, reflecting a broader industry trend of consolidation and specialization in the medical device sector.

Comparison to Industry Standards

• The document mentions a peer group including Abbott Laboratories, Medtronic, and Stryker, suggesting Boston Scientific benchmarks its performance and compensation against these industry leaders.
• The document references the Dow Jones Sustainability Index North America (DJSI), indicating a commitment to environmental, social, and governance (ESG) factors, aligning with increasing industry focus on sustainability.

Related Party Transactions

• In 2024, the Companys Nominating and Governance Committee reviewed and pre-approved related party transactions with Joseph Barrett Fitzgerald and Robert Blaise Fitzgerald, the sons of Joseph Fitzgerald, our Executive Vice President and Group President, Cardiology.

Stakeholder Impact

• The company aims to increase value for customers, employees, and stockholders.
• The company's devices and therapies help physicians diagnose and treat complex diseases and conditions.
• The company is committed to improving the health of people and the planet.

Next Steps

• Stockholders are encouraged to vote their shares via the internet, telephone, or mail.
• The company will continue to focus on its long-range financial goals and strategic imperatives.
• The company will continue to monitor and evaluate its corporate governance practices.

Key Dates

Keywords

stockholders, Boston Scientific, Annual Meeting, executive compensation, directors, acquisitions, medical devices, financial performance